| Code | CSB-RA552120A0HU |
| Size | US$210 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
| FC | 1:50-1:200 |
IKZF3, also known as Aiolos, is a zinc finger transcription factor belonging to the Ikaros family that plays essential roles in lymphocyte development and immune regulation. This transcription factor is particularly critical for B cell maturation and differentiation, where it regulates genes involved in B cell receptor signaling and survival. IKZF3 has gained significant attention in cancer research due to its involvement in hematological malignancies, and it serves as a key target for immunomodulatory drugs used in multiple myeloma treatment, making it a valuable marker for both basic immunology and translational oncology studies.
This recombinant monoclonal antibody, generated from clone 9E9 in rabbit host, offers the reproducibility and consistency that demanding research protocols require. Because the antibody sequence is defined and produced recombinantly, you can expect uniform performance across experiments and over time, eliminating the lot-to-lot variability that can complicate long-term studies or multi-site collaborations. Affinity chromatography purification ensures high specificity for your target.
Validation testing demonstrates reliable performance across multiple applications. Immunohistochemistry studies in paraffin-embedded human tissues, including glioma and spleen sections, show clear detection using citrate buffer antigen retrieval at dilutions of 1:100. Flow cytometry analysis using Raji cells, a well-established B cell lymphoma line, confirms intracellular detection of IKZF3 with distinct signal separation from isotype controls. These validated applications provide flexibility for researchers investigating IKZF3 in both tissue-based and cell-based experimental systems.
Whether you are exploring lymphocyte biology, investigating therapeutic mechanisms of immunomodulatory compounds, or characterizing IKZF3 expression in malignancies, this antibody delivers the performance and consistency your research demands.
There are currently no reviews for this product.